Dr. Rastetter serves as Chairman of the Board of Directors. He has served as a member of the Board since January 2014, when the Company was known as Cerulean Pharma, Inc., and previously served as Chairman of the Board from June 2016 through July 2017. He continued to serve on the Board of Directors following Cerulean’s combination with Daré and was appointed Chairman of the Board in July 2019.
Dr. Rastetter currently serves as Chairman of the board of directors of GRAIL, Neurocrine Biosciences and Fate Therapeutics, and as a member of the board of directors of Regulus Therapeutics. Dr. Rastetter co-founded the biopharmaceutical company, Receptos, where he held the roles of Acting CEO from 2009 to 2010, and Director and Chairman of the board of directors from 2009 to 2015. Dr. Rastetter served on the board of directors of Illumina, a leading publicly-traded genomic technology company, from 1998 until January 2016, and as Chairman from 2005 to 2016. Dr. Rastetter was a partner at the venture capital firm Venrock Associates from 2006 to 2013. Prior to his tenure with Venrock, Dr. Rastetter was Executive Chairman of Biogen Idec after having previously served as Chairman and CEO of Idec Pharmaceuticals. Dr. Rastetter served as a Director of Corporate Ventures at Genentech. Dr. Rastetter held various faculty positions at the Massachusetts Institute of Technology and Harvard University and is an Alfred P. Sloan Fellow. Dr. Rastetter holds an SB from the Massachusetts Institute of Technology and received his MA and PhD from Harvard University.